
Opinion|Videos|November 12, 2024
New Data from AANEM 2024 in Generalized Myasthenia Gravis
Key Takeaways
- Gene therapy advancements for inherited neuromuscular disorders were a significant focus, highlighting potential transformative impacts on treatment paradigms.
- Novel pharmacological interventions targeting specific molecular pathways showed promise, indicating a shift towards more targeted therapeutic approaches.
Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.
Advertisement
Video content above is prompted by the following:
- Please share other interesting/practice-impacting data that were presented at AANEM 2024.
- What other emerging treatments are you excited about?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne
2
Priority Review Granted for Weekly Subcutaneous Lecanemab Dosing in Early Alzheimer Disease
3
Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial
4
FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials
5










